Annual Report 2020

NOTESTOTHE CONSOLIDATED FINANCIAL STATEMENTS For the year ended 31 December 2020 85 The United Laboratories International Holdings Limited Annual Report 2020 5. REVENUE AND SEGMENT INFORMATION (Continued) Segment information (Continued) (b) Other segment information (Continued) For the year ended 31 December 2019 Intermediate Bulk Finished products medicine products Unallocated Consolidated RMB’000 RMB’000 RMB’000 RMB’000 RMB’000 Amortisation of intangible assets 1,840 – 10,767 – 12,607 Depreciation of right-of-use assets 71,293 2,018 1,387 – 74,698 Depreciation of property, plant and equipment 444,576 84,404 51,752 7,695 588,427 Net loss on disposal of property, plant and equipment 13,560 802 49 – 14,411 Impairment losses recognised (reversed) 1,376 (737) (2,990) 10,006 7,655 (c) Geographical information The revenue by geographical market (irrespective of the origin of the goods) based on the location of the customers are presented below: Revenue from external customers 2020 2019 RMB’000 RMB’000 PRC, including Hong Kong (country of domicile) 6,259,058 6,045,514 Europe 730,289 642,620 India 818,938 833,723 Middle East 58,040 44,353 South America 227,875 234,337 Other Asian regions 421,103 366,692 Other regions 257,185 225,361 8,772,488 8,392,600